Recurrence of primary sclerosing cholangitis, primary biliary cholangitis and auto-immune hepatitis after liver transplantation
Liver transplantation is a well-accepted treatment for decompensated chronic liver disease due to primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC) and auto-immune hepatitis (AIH). Survival after liver transplantation is generally good with 1 and 5-year survival rates around 90% and 70-85%. After transplantation, however, these diseases recur in 8.6-27% (rPSC), 10.9-42.3% (rPBC) and 7-42% (rAIH), and this poses significant challenges in terms of management and graft outcome in these patients. In this review we discuss the incidence, clinical presentation, challenges in diagnosis, reported risk factors and impact on post-transplant outcomes of recurrence of PSC, PBC and AIH after liver transplantation. We also discuss some of the limitations of current investigations and formulate idea's for future research objectives.
|Keywords||Autoimmune hepatitis, Liver transplantation, Primary biliary cholangitis, Primary sclerosing cholangitis, Recurrence|
|Persistent URL||dx.doi.org/10.1016/j.bpg.2017.04.004, hdl.handle.net/1765/99719|
|Journal||Best Practice and Research in Clinical Gastroenterology|
Visseren, T, & Darwish Murad, S. (2017). Recurrence of primary sclerosing cholangitis, primary biliary cholangitis and auto-immune hepatitis after liver transplantation. Best Practice and Research in Clinical Gastroenterology (Vol. 31, pp. 187–198). doi:10.1016/j.bpg.2017.04.004